Clearmind Medicine Inc is a biotechnology company focused on developing innovative therapeutics aimed at treating mental health disorders
The company leverages its expertise in psychedelic research to create novel compounds that can address conditions such as depression, anxiety, and addiction. By combining advanced scientific approaches with an emphasis on safety and efficacy, Clearmind aims to revolutionize the way mental health issues are treated, ultimately improving patient outcomes and quality of life. Their commitment to rigorous clinical trials and research positions them at the forefront of the emerging field of psychedelic medicine.
Clearmind Medicine secures a U.S. patent for its MEAI-based binge behavior treatment, marking a significant advancement in addressing Alcohol Use Disorder.
Clearmind Medicine shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office.
Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the no/low alcohol category is forecasted to grow at a volume CAGR of more than 6% between 2023 and 2027.
Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development.
Shares of Taysha Gene Therapies, Inc. (NASDAQTSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results.
